Enliven Therapeutics
ELVN
74 hedge funds and large institutions have $781M invested in Enliven Therapeutics in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 3 closing their positions.
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
44% more capital invested
Capital invested by funds: $541M → $781M (+$240M)
19% more funds holding
Funds holding: 62 → 74 (+12)
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
12.68% more ownership
Funds ownership: 94.83% → 107.51% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$19.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.6M |
| 3 |
CC
Commodore Capital
New York
|
+$16.4M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$16.4M |
| 5 |
VA
VR Adviser
New York
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$20.3M |
| 2 |
Morgan Stanley
New York
|
-$1.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$731K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$614K |
| 5 |
BlackRock
New York
|
-$557K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$61 | +4 | New |
|
ELVN Hedge Fund Activity: Q1 2024 in Review
74 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2024, worth a combined $781M — up 44% from $541M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ELVN positions and 3 closed out — a net gain of 13 holders — while 25 added to existing stakes and 22 trimmed.
The largest buyer was Logos Global Management, adding an estimated $19.4M. The largest seller was 5AM Venture Management, cutting an estimated $20.3M.
- 74 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2024, up from 62 in Q4 2023.
- Funds reported $781M of Enliven Therapeutics stock for Q1 2024, up 44% quarter-over-quarter.
- 16 funds opened new Enliven Therapeutics positions in Q1 2024 and 3 closed out, a net change of +13 holders.
- The largest Enliven Therapeutics buyer in Q1 2024 was Logos Global Management, an estimated $19.4M added.
- The largest Enliven Therapeutics seller in Q1 2024 was 5AM Venture Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q1 2024.